

BIBLIOGRAPHIE DU PROGRAMME

1. Ashwell M, Gunn P, Gibson S. Waist-to-height ratio is a better screening tool than waist circumference and BMI for adult cardiometabolic risk factors: systematic review and meta-analysis. *Obes Rev.* 2012;13(3):275-286. doi:[10.1111/j.1467-789X.2011.00952.x](https://doi.org/10.1111/j.1467-789X.2011.00952.x)
2. Barry E, Roberts S, Oke J, Vijayaraghavan S, Normansell R, Greenhalgh T. Efficacy and effectiveness of screen and treat policies in prevention of type 2 diabetes: systematic review and meta-analysis of screening tests and interventions. *BMJ.* Published online January 4, 2017:i6538. doi:[10.1136/bmj.i6538](https://doi.org/10.1136/bmj.i6538)
3. Bourassa D. Le syndrome des ovaires polykystiques nouveautés en matière d'investigation et de traitement de l'infertilité. *Méd du Québec.* 2002;37(11-2):55-63.
4. Carolina JL PharmD, BCACP, CDCES, CPP Clinical Staff Pharmacist Fort Mill, South Carolina Alexis Robinson, PharmD Clinical Staff Pharmacist Charlotte, North. Detecting and Managing Drug-Induced Diabetes. *US Pharmacist.* Published 2021. Accessed September 20, 2023. <https://www.uspharmacist.com/article/detecting-and-managing-druginduced-diabetes>
5. Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. *Lancet.* 2021;397(10278):971-984. doi:[10.1016/S0140-6736\(21\)00213-0](https://doi.org/10.1016/S0140-6736(21)00213-0)
6. Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetologia.* 2022;65(12):1925-1966. doi:[10.1007/s00125-022-05787-2](https://doi.org/10.1007/s00125-022-05787-2)
7. Del Prato S, Kahn SE, Pavo I, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. *Lancet.* 2021;398(10313):1811-1824. doi:[10.1016/S0140-6736\(21\)02188-7](https://doi.org/10.1016/S0140-6736(21)02188-7)
8. Ekoe JM, Goldenberg R, Katz P. Screening for Diabetes in Adults. *Can J Diabetes.* 2018;42:S16-S19. doi:[10.1016/j.jcid.2017.10.004](https://doi.org/10.1016/j.jcid.2017.10.004)
9. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. *N Engl J Med.* 2021;385(6):503-515. doi:[10.1056/NEJMoa2107519](https://doi.org/10.1056/NEJMoa2107519)
10. Frias JP, Deenadayalan S, Erichsen L, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. *Lancet.* 2023;402(10403):720-730. doi:[10.1016/S0140-6736\(23\)01163-7](https://doi.org/10.1016/S0140-6736(23)01163-7)
11. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. *Nat Med.* 2022;28(10):2083-2091. doi:[10.1038/s41591-022-02026-4](https://doi.org/10.1038/s41591-022-02026-4)
12. Goguen J, Gilbert J. Hyperglycemic Emergencies in Adults. *Can J Diabetes.* 2018;42:S109-S114. doi:[10.1016/j.jcid.2017.10.013](https://doi.org/10.1016/j.jcid.2017.10.013)
13. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. *BMC Public Health.* 2009;9:88. doi:[10.1186/1471-2458-9-88](https://doi.org/10.1186/1471-2458-9-88)
14. Hosler AS. Peer Reviewed: Prevalence of Self-Reported Prediabetes Among Adults Participating in a Community-Based Health Awareness Program, New York State. *Prev Chronic Dis.* 2009;6(2). Accessed March 4, 2024. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687854/>
15. Jain V, Patel RK, Kapadia Z, Galiveeti S, Banerji M, Hope L. Drugs and hyperglycemia: A practical guide. *Maturitas.* 2017;104:80-83. doi:[10.1016/j.maturitas.2017.08.006](https://doi.org/10.1016/j.maturitas.2017.08.006)

Agir sur l'effet domino

Stratégies précoces pour prévenir
Les complications du diabète de type 2

16. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. *N Engl J Med*. 2023;389(6):514-526. doi:[10.1056/NEJMoa2301972](https://doi.org/10.1056/NEJMoa2301972)
17. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. *Kidney Int*. 2022;102(5S):S1-S127. doi:[10.1016/j.kint.2022.06.008](https://doi.org/10.1016/j.kint.2022.06.008)
18. Knop FK, Aroda VR, Vale RD do, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*. 2023;402(10403):705-719. doi:[10.1016/S0140-6736\(23\)01185-6](https://doi.org/10.1016/S0140-6736(23)01185-6)
19. Li C, Ford ES, Zhao G, Croft JB, Balluz LS, Mokdad AH. Prevalence of self-reported clinically diagnosed sleep apnea according to obesity status in men and women: National Health and Nutrition Examination Survey, 2005-2006. *Prev Med*. 2010;51(1):18-23. doi:[10.1016/j.ypmed.2010.03.016](https://doi.org/10.1016/j.ypmed.2010.03.016)
20. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. *N Engl J Med*. 2023;0(0):null. doi:[10.1056/NEJMoa2307563](https://doi.org/10.1056/NEJMoa2307563)
21. Lipscombe L, Butalia S, Dasgupta K, et al. Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update. *Can J Diabetes*. 2020;44(7):575-591. doi:[10.1016/j.jcjd.2020.08.001](https://doi.org/10.1016/j.jcjd.2020.08.001)
22. Look AHEAD Research Group, Wing RR, Bolin P, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. *N Engl J Med*. 2013;369(2):145-154. doi:[10.1056/NEJMoa1212914](https://doi.org/10.1056/NEJMoa1212914)
23. Ludvik B, Giorgino F, Jódar E, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. *Lancet*. 2021;398(10300):583-598. doi:[10.1016/S0140-6736\(21\)01443-4](https://doi.org/10.1016/S0140-6736(21)01443-4)
24. Luppino FS, de Wit LM, Bouvy PF, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. *Arch Gen Psychiatry*. 2010;67(3):220-229. doi:[10.1001/archgenpsychiatry.2010.2](https://doi.org/10.1001/archgenpsychiatry.2010.2)
25. MacKay D, Chan C, Dasgupta K, et al. Remission of Type 2 Diabetes. *Can J Diabetes*. 2022;46(8):753-761.e8. doi:[10.1016/j.jcjd.2022.10.004](https://doi.org/10.1016/j.jcjd.2022.10.004)
26. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med*. 2016;375(4):311-322. doi:[10.1056/NEJMoa1603827](https://doi.org/10.1056/NEJMoa1603827)
27. McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis. *JAMA Cardiol*. 2021;6(2):148-158. doi:[10.1001/jamacardio.2020.4511](https://doi.org/10.1001/jamacardio.2020.4511)
28. Memon AN, Gowda AS, Rallabhandi B, et al. Have Our Attempts to Curb Obesity Done More Harm Than Good? *Cureus*. 2020;12(9):e10275. doi:[10.7759/cureus.10275](https://doi.org/10.7759/cureus.10275)
29. Meneilly GS, Knip A, Miller DB, Sherifali D, Tessier D, Zahedi A. Diabetes in Older People. *Can J Diabetes*. 2018;42:S283-S295. doi:[10.1016/j.jcjd.2017.10.021](https://doi.org/10.1016/j.jcjd.2017.10.021)
30. Monographie de Mounjaro. Eli Lilly Canada Inc. Date d'approbation initiale : 23 novembre 2022
31. Monographie de Wegovy. Novo Nordisk Canada Inc. Date de révision : 29 juin 2023
32. Monographie de Saxenda. Novo Nordisk Canada Inc. Date de révision : 9 décembre 2022
33. Monographie de Contrave. Bausch Health, Canada Inc. Date de révision : 21 août 2023
34. Monographie de Xenical. CHEPLAPHARM Arzneimittel GmbH. Date de révision : 5 juillet 20223
35. Novo Nordisk. Press Release: Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial. Novo Nordisk. Published August 2023. Accessed October 17, 2023. <https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html>

Agir sur l'effet domino

Stratégies précoces pour prévenir
Les complications du diabète de type 2

36. Pedersen SD, Manjoo P, Wharton S. Pharmacotherapy for obesity management: 2022 update. *Obesity Canada*. Published online 2022. Accessed September 21, 2023. https://obesitycanada.ca/wp-content/uploads/2022/10/Pharmacotherapy-CPG-2022_final.pdf
37. Perkovic V, Tuttle KR, Rossing P, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. *N Engl J Med*. Publié en ligne le 24 mai 2024. doi:10.1056/NEJMoa2403347
38. Punthakee Z, Goldenberg R, Katz P. Definition, Classification and Diagnosis of Diabetes, Prediabetes and Metabolic Syndrome. *Can J Diabetes*. 2018;42:S10-S15. doi:10.1016/j.jcid.2017.10.003
39. Rehman A, Setter SM, Vue MH. Drug-Induced Glucose Alterations Part 2: Drug-Induced Hyperglycemia. *Diabetes Spectrum*. 2011;24(4):234-238. doi:10.2337/diaspect.24.4.234
40. Roberts A, James J, Dhatariya K. Management of Hyperglycaemia and Steroid (Glucocorticoid) Therapy. *JBDS-IP*. Published online 2014. Accessed September 20, 2023. https://www.diabetes.org.uk/resources-s3/2017-09/JBDS%20management%20of%20hyperglycaemia%20and%20steroid%20therapy_0.pdf
41. Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. *Lancet*. 2021;398(10295):143-155. doi:10.1016/S0140-6736(21)01324-6
42. Rossing P, Caramori ML, Chan JCN, et al. Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence. *Kidney Int*. 2022;102(5):990-999. doi:10.1016/j.kint.2022.06.013
43. Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. *JAMA*. 2021;325(14):1414-1425. doi:10.1001/jama.2021.3224
44. Rubino DM, Greenway FL, Khalid U, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. *JAMA*. 2022;327(2):138-150. doi:10.1001/jama.2021.23619
45. Salminen P, Helmiö M, Ovaska J, et al. Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss at 5 Years Among Patients With Morbid Obesity: The SLEEVEPASS Randomized Clinical Trial. *JAMA*. 2018;319(3):241-254. doi:10.1001/jama.2017.20313
46. Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. *Lancet Diabetes Endocrinol*. 2021;9(10):653-662. doi:10.1016/S2213-8587(21)00203-5
47. Senior PA, Houlden RL, Kim J, et al. Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update – The User’s Guide. *Can J Diabetes*. 2020;44(7):592-596. doi:10.1016/j.jcid.2020.08.002
48. Shah P, Kalra S, Yadav Y, et al. Management of Glucocorticoid-Induced Hyperglycemia. *DMSO*. 2022;Volume 15:1577-1588. doi:10.2147/DMSO.S330253
49. Sievenpiper JL, Chan CB, Dworatzek PD, Freeze C, Williams SL. Nutrition Therapy. *Can J Diabetes*. 2018;42:S64-S79. doi:10.1016/j.jcid.2017.10.009
50. Simon GE, Von Korff M, Saunders K, et al. Association between obesity and psychiatric disorders in the US adult population. *Arch Gen Psychiatry*. 2006;63(7):824-830. doi:10.1001/archpsyc.63.7.824
51. Srivastava G, Apovian C. Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon. *Curr Obes Rep*. 2018;7(2):147-161. doi:10.1007/s13679-018-0300-4
52. Teede HJ. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. *Eur J Endo*. 2023;189(2).

Agir sur l'effet domino

Stratégies précoces pour prévenir
Les complications du diabète de type 2

53. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. *Diabetes Care*. 2004;27(1):155-161. doi:[10.2337/diacare.27.1.155](https://doi.org/10.2337/diacare.27.1.155)
54. Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. *JAMA*. 2021;325(14):1403-1413. doi:[10.1001/jama.2021.1831](https://doi.org/10.1001/jama.2021.1831)
55. Wharton S, Blevins T, Connery L, et al. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. *N Engl J Med*. 2023;389(10):877-888. doi:[10.1056/NEJMoa2302392](https://doi.org/10.1056/NEJMoa2302392)
56. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. *N Engl J Med*. 2021;384(11):989-1002. doi:[10.1056/NEJMoa2032183](https://doi.org/10.1056/NEJMoa2032183)
57. Williams DM, Nawaz A, Evans M. Drug Therapy in Obesity: A Review of Current and Emerging Treatments. *Diabetes Ther*. 2020;11(6):1199-1216. doi:[10.1007/s13300-020-00816-y](https://doi.org/10.1007/s13300-020-00816-y)
58. Williams T, Moore JB, Regehr J. Polycystic Ovary Syndrome: Common Questions and Answers. *AFP*. 2023;107(3):264-272.
59. Les urgences hyperglycémiques | Diabète Québec. Published September 15, 2014. Accessed September 20, 2023. <https://www.diabete.qc.ca/le-diabete/informations-sur-le-diabete/urgences-diabetiques/les-urgences-hyperglycemiques/>
60. Cadre sur le diabète au Canada : Infographie. Published November 24, 2022. Accessed September 7, 2023. <https://www.canada.ca/fr/sante-publique/services/publications/maladies-et-affections/cadre-diabete-canada-infographie.html>